Drug Approval | October 02, 2024
Zydus receives EIR for the transdermal manufacturing facility
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
Sets price band at ?695 to ?735 per Equity Share
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The programme was conducted as a part of MPMCx, an exclusive management programme for MBBS doctors by IIM-Ahmedabad in collaboration with DailyRounds
The business and product range of Ipca and that of Unichem complements each others business and product range
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
Subscribe To Our Newsletter & Stay Updated
